Baseline characteristics (N=27)
| Variable | n | % |
| All | 27 | 100 |
| Age at diagnosis, years | ||
| Median (mean) | 60 (57.6) | |
| Range | 36–74 | |
| Age at trial start, years | ||
| Median (mean) | 64 (62) | |
| Range | 42–76 | |
| gBRCA mutated (missing=7) | ||
| BRCA1+ | 1 | 5 |
| BRCA2+ | 1 | 5 |
| WT | 18 | 90 |
| sBRCA mutated (missing=20) | ||
| BRCA2+ | 3 | 42.9 |
| WT | 4 | 57.1 |
| Histology | ||
| Clear cell | 2 | 7.4 |
| Endometrioid | 1 | 3.7 |
| High grade serous (HGS) | 23 | 85.2 |
| Mixed | 1 | 3.7 |
| Number of lines of therapy | ||
| Median (mean) | 4 (4) | |
| Range | 1–8 | |
| PFI in months | ||
| Median (mean) | 1 (1.9) | |
| Range | 0–6 |
PFI, platinum-free interval; WT, wild type.